NDAORALTABLET
Approved
Aug 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
FENOGLIDE (fenofibrate) by Salix Pharmaceuticals is α (pparα). Approved for hypertriglyceridemia, dyslipidemia, hypercholesterolemia and 2 more indications. First approved in 2007.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FENOGLIDE (fenofibrate) is an oral small-molecule fibrate that activates PPARα to reduce triglycerides and improve lipid profiles in patients with dyslipidemia and hypertriglyceridemia. It works by increasing lipolysis, reducing VLDL production, and shifting LDL particles to larger, less atherogenic forms while raising HDL cholesterol. The drug also reduces serum uric acid levels through increased urinary excretion.
LOE Approaching
With LOE approaching and a competitive pressure index of 30, the FENOGLIDE brand team is likely in defensive/optimization mode with lean staffing focused on market retention rather than expansion.
Mechanism of Action
α (PPARα). Through this mechanism, fenofibrate increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor of lipoprotein lipase activity). The resulting fall in triglycerides produces an…
Indications (5)
Worked on FENOGLIDE at Salix Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.